Nick Kreusser’s Post

things getting more and more interesting in our field #bioinformatics #nextflow #genomics

I had the pleasure to attend the BioIndustry Association (BIA) #Techbio conference and AlbionVC's recent techbio breakfast, both of which highlighted the exciting potential of computational drug discovery. Key takeaways: 🧠 Actionable insights are key: With knowledge becoming commoditised, execution is paramount in this nascent industry 🧬 Techbio's broad impact: Developments in early-stage drug discovery are incredibly exciting (a highlight being Isomorphic Labs' keynote on their latest multi-omic work with AlphaFold 3), though techbio is revolutionising the entire life sciences supply chain, from early R&D to real-time monitoring 🧪 Platform vs. product: Defining a company's focus remains crucial - but may well shift - especially as datasets expand, and confidence grows in the outputs and findings of computational modelling 🤝 Strategic partnerships: Securing aligned advice, support, and investment is crucial. Clear expectations from the outset are vital to bridge the knowledge gap between tech and bio stakeholders and navigate the unique challenges of this field We are still very much at the foothills of the techbio journey, and I'm looking forward to what the next twelve months bring! #Techbio2024 #DrugDiscovery #PrecisionMedicine #EngineeringBiology #AI #Data #Genomics

At the annual Decoding Bio summit, I sat down with Brad Loncar of BiotechTV to discuss how we at Bessemer Venture Partners are thinking about where value accrues for AI in biotech. The short answer: Ultimate value accrues at the therapeutic level. Longer answer: If AI improves drug discovery along any axis (speed, efficiency, cost, new biology, novel chemistry), and becomes a near-ubiquitous tool in the discovery process, value will accrue up the stack. Vertical integration of discovery and development will be essential to capture this value, and the greatest moats will (still) be built in clinical development – trial design, biomarker identification, indication selection, and raw execution.

#AI in #chemistry is made easy. Just add data, to build your own #informatics #machinelearning #models automatically with explainable and actionable insights.

In any given moment, we have two options: to step forward into growth or step back into safety - Abraham Maslow As the #pharmaceutical industry is experiencing a revolution driven by artificial intelligence and massive computing power, this decision is more critical than ever.… If #AI simplifies work by analyzing, filtering, sorting, predicting and recognizing huge volumes of data, ELEM’s #virtualhumans, developed in Barcelona Supercomputing Center's MareNostrum and deployed in a supercomputing cloud, are revolutionizing therapeutics development and patient prognosis, enabling large-scale reliable in-silico #clinicaltrials.  To step forward into the future of healthcare with ELEM, contact us at contact@elem.bio and request a demo of our platform. The future is now! #medtech #Healthtech #EUeic

As with other industries, Loper Bright has the potential to shake up life sciences/healthcare sectors. Reflecting on the discussions of last week and looking towards next, I have questions, not long enough for a discussion but perfect for a short video. And I will be asking these questions and sharing these thoughts with Christopher Escobedo Hart next week during #ScopeEU. #LoperBright #FDA #AI #biotech #techbo #lifesciences #drugdevelopment #BioSpace BioSpace

I am currently on my way to the Scottish Life Sciences Summit 2024, which is taking place in Aberdeen on March 20th. This is my first time attending this event, and I'm excited to see what it has in store. The summit promises to bring together investors, entrepreneurs and other industry leaders to explore how to transform innovative ideas into commercial realities. The main topics for discussion this year include: ➡️ Unlocking the power of genetic data ➡️ Exploring the future of AI and its applications in biotech ➡️ Understanding how venture capitalists make their investment choices in life sciences One of the hot topics expected to be discussed at the event is the use of AI to accelerate drug discovery, which is why I am eager to be there 😊 Have you had the opportunity to attend this forum before? #lifescience #clinicaldevelopment #biotech

From recent #biotech financings to regulating AI in #medtech, here’s what’s happening in life sciences.

🧬 Happy DNA Day! 🧬 Today, April 25th, we celebrate National DNA Day, commemorating the groundbreaking discovery of the double helix structure of DNA by James Watson, Francis Crick, Maurice Wilkins, and Rosalind Franklin in 1953. This remarkable achievement has propelled forward the fascinating field of genomics – the study of the complete set of DNA, including all its genes, in a person or other organism. The UK is a world leader in this domain, having successfully completed the 100k Genomes Project in 2018. This initiative not only continues to yield immense benefits for patients but also showcases the enormous potential of genomics in healthcare. From advancing medical breakthroughs to revolutionising how we treat diseases, the impact of genomics is profound and far-reaching. On this special day, let's also appreciate the intricate beauty of the human blueprint. As we commemorate this milestone, I invite you to join in the conversation: How do you think DNA research will evolve in the next decade, and what impacts do you foresee in our daily lives? #DNADay #Genomics #Biotech #ScienceInnovation #PersonalizedMedicine #tech #techbio #ai #startups #drugdiscovery #aptamers #oligos #generativeai #biotech #community #pharma #artificialintelligence #venturecapital #startups

Congratulations to Shift Bioscience who has secured £12.5 million in Seed Investment led by BGF Shift Bioscience is a biotech company using generative AI models to understand how activation of different genes can reverse the aging process. This research is a fundamental step forward in designing more effective drugs to treat age-related diseases. The company has announced that it has raised $16M (£12.5M) in Seed funding, led by BGF, with existing investors F-Prime Capital, Kindred Capital, and Jonathan Milner participating. The investment will be used for the continued development of Shift Bioscience’s artificial intelligence (AI) cell simulation platform, for the identification of genes that can safely rejuvenate cells to combat the effects of age-related illnesses. Find out more via Deal Lite https://lnkd.in/djTVYnxs #Biotech #GenerativeAI #AgingResearch #SeedFunding #HealthTech #InvestInInnovation #DrugDevelopment #AIInHealthcare #AgeRelatedDiseases #UKTech